Health tech firms deploying predictive diagnostic algorithms are confronting stricter compliance hurdles as global health authorities tighten Software as a Medical Device (SaMD) classifications. Retrospective data studies are no longer sufficient for regulatory approval.
Clinical Trial Requirements
Developers must now conduct randomized multi-center prospective trials to demonstrate diagnostic safety and efficacy. The increased regulatory burden is extending market entry timelines and raising initial capital requirements for medical AI startups.